Company Overview
Astria Therapeutics, Inc. operates as a biopharmaceutical entity focused on the discovery, development, and commercialization of therapeutics specifically designed for allergic and immunological diseases within the United States market. The company positions itself within the broader Healthcare sector, functioning specifically in the Biotechnology industry, which implies a reliance on high-risk research and development cycles to bring novel biological agents to patients. In terms of organizational scale, the company employs 78 individuals and carries a market capitalization of $718.13M, while generating annual revenue of $706,000 over the trailing twelve-month period. These financial dimensions indicate that Astria Therapeutics is a small-cap biotechnology firm with a valuation significantly higher than its current revenue generation, a common characteristic of early-stage companies prioritizing pipeline advancement over immediate profitability.
Financial Health
The financial statements for the trailing twelve months show a revenue of $706,000 contrasted against a net income of $-124,030,000, revealing a substantial gap that underscores a heavy cost structure typical of biotechnology firms burning capital on research and development. While the EBITDA metric is listed as N/A, the absence of positive earnings before interest, taxes, depreciation, and amortization alongside the negative net income highlights the aggressive expenditure required to advance the lead product candidate, navenibart. The company reports a free cash flow of $-80,486,752, indicating a significant cash outflow that limits immediate financial flexibility and necessitates continued access to external capital markets to sustain operations. Margin analysis reveals a gross margin of 100.0%, suggesting that the cost of goods sold is negligible relative to revenue, yet this is offset by an operating margin of -4830.6% and a profit margin of 0.0%, illustrating that operating expenses far exceed revenue generation. On the balance sheet, the company holds $227.72M in cash against $4.46M in debt, resulting in a debt-to-equity ratio of 1.91, which suggests a leveraged position where equity is less than double the debt load. Liquidity is robustly supported by a current ratio of 10.78, indicating that short-term assets are more than ten times the value of short-term liabilities, providing a strong buffer against immediate obligations. Return metrics show a return on equity of -43.1% and a return on assets of -26.9%, reflecting that management's effectiveness in generating profit is currently negative due to the high burn rate rather than operational inefficiency.
Valuation Assessment
Valuation multiples for Astria Therapeutics, Inc. present a mixed picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings and a forward P/E of -5.29, which implies the market is pricing in future profitability that has not yet materialized in current financial results. The price-to-book ratio stands at 5.15, indicating that the market values the company at a significant premium over its net asset book value, likely reflecting the high potential value of its intellectual property and pipeline assets. Alternative valuation metrics include a price-to-sales ratio of 1017.18 and an EV/EBITDA of N/A, figures that suggest the stock is priced based on speculative future growth expectations rather than current cash flows or earnings power. In terms of trading range, the stock has a 52-week high of $13.29 and a 52-week low of $3.56, meaning the current price sits somewhere within this volatility band relative to the year's extremes. The beta value is recorded at 0.02, which indicates extremely low price volatility relative to the broader market, suggesting the stock price movements are largely decoupled from general market indices.
Growth & Income
Growth metrics for the company show revenue growth (YoY) and earnings growth (YoY) both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue within the current reporting period. As the company does not pay a dividend, the dividend yield and payout ratio are both N/A and 0.0% respectively, indicating that the company reinvests all available earnings and cash reserves back into research, development, and operational growth rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms in the development phase, where capital is required to advance clinical trials and secure regulatory approvals for navenibart. The overall growth and income profile is characterized by zero current income distribution and undefined growth rates due to the absence of profitability, focusing entirely on capital deployment for future therapeutic potential.